A randomized phase II trial of sunitinib administered daily for 4 weeks, followed by 2-week rest vs. 2-week on and 1-week off in metastatic renal cell carcinoma.

Trial Profile

A randomized phase II trial of sunitinib administered daily for 4 weeks, followed by 2-week rest vs. 2-week on and 1-week off in metastatic renal cell carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2011 Planned number of patients changed from 72 to 80 as reported by ClinicalTrials.gov.
    • 05 Dec 2011 Planned end Ddte changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 05 Dec 2011 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top